Skip to main content
Article thumbnail
Location of Repository

Letter from the Editor...

By Immune Drug Interactions

Abstract

Since 1983, when Sandimmune ® (cyclosporine) was approved, we have witnessed a medical miracle: the transition of organ transplantation from a desperate, experimental gamble to a procedure that is so much a part of medical therapy that our greatest problem today is supplying sufficient donor organs to meet the enormous demand. Transplant recipients are to be found at every age and in every walk of life, not simply existing, but living full, fulfilling and lengthy lives. Over the years, the Sandimmune Drug Interaction book has been in great demand, and we have been honored to provide it to the medical community as a service. A new formulation of cyclosporine, Neoral ® (cyclosporine capsules and oral solution, USP) MODIFIED became available in 1995; indications for treatment resistant rheumatoid arthritis and recalcitrant psoriasis were obtained soon after, and the transition to a new company, Novartis Pharmaceuticals Corporation occurred over the course of 1997. Our commitment to providing this service is, however, unchanged, and we are pleased to provide this valuabl

Year: 2002
OAI identifier: oai:CiteSeerX.psu:10.1.1.196.8431
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://citeseerx.ist.psu.edu/v... (external link)
  • http://www.novartis-transplant... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.